Home » Topics » Disease categories and therapies » Nephrology

Nephrology
RSS

KW-7158 to enter phase II trials in Europe for treatment of urinary incontinence

June 8, 2001

Uroselective alpha1A/1L-adrenoceptor antagonists designed by Italian investigators

June 7, 2001

AUA news: first use of stem cells to regenerate and restore function in sphincter muscle

June 7, 2001

Phytotherapy compared to alpha-adrenoceptor blockade with tamsulosin in BPH

June 7, 2001

Tamsulosin highlighted at AUA meeting

June 7, 2001

Bayer's new PDE5 inhibitor improves ED over 12 weeks of therapy

June 6, 2001

ET antagonists may have therapeutic role in diabetic erectile dysfunction

June 6, 2001

Patent covers Ferring's new vasopressin V2 receptor agonists and uses

June 5, 2001

Palatin's PT-141 ED treatment well tolerated in phase I trial

June 5, 2001

AUA news: AII antagonist, ACE inhibitor protect against postischemic acute renal failure

June 5, 2001

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
Chengdu Mfs Pharma synthesizes new compounds for pain
BioWorld Science
Chengdu Mfs Pharma Co. Ltd. has prepared and tested compounds for the potential treatment of pain, sleep disorder and status epilepticus epilepsy as well as for...